Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer

Azacitidine will be given with standard dose of cisplatin. At the beginning of the study, three patients will be treated with low dose of azacitidine. If that dose does not cause bad side effects, then the dose will slowly be made higher for new patients who take part in the study. Patients will receive azacitidine as a once-a-day subcutaneous (under the skin) injection every day from day 1 to day 5 of 28 days in this study. Cisplatin is given intravenously on day 8. This 28-day or 4-week period of time is called a cycle. Cycles are repeated every four weeks for as long as the physician recommends. During this study, patients will need the following tests and procedures. * Physical exam - This will be done weekly during first 2 weeks of every 4-week treatment cycle. * Blood tests for blood counts - These will be done every week. * Blood tests for kidney function, liver function, and to measure electrolytes - These will be done every week * Blood samples for research study - This will be done weekly during first cycle, then weekly during the first 2 weeks on the subsequent treatment cycles * X-rays or scans - These will be done once every 8 weeks.